In vitro evaluation of an enhanced human Serum Amyloid A (SAA2) promoter-regulated soluble TNF receptor fusion protein for anti-inflammatory gene therapy

Scandinavian Journal of Immunology

Volumn 53, Issue 6, 2001, Pages 588-595

  Rygg, M ^a,c,d   Uhlar, C M ^a,e   Thorn, C ^a   Jensen, L E ^a   Gaughan, D J ^a   Varley, A W ^b   Munford, R S ^b   Goke R ^a   Chen, Y ^a   Whitehead, A S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d PFIZER INC   (United States)

^e ICON CLINICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE FUSION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; INFLAMMATION; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REPORTER GENE; RHEUMATOID ARTHRITIS; TRANSCRIPTION REGULATION;

ARTHRITIS, RHEUMATOID; GENE THERAPY; GENES, REPORTER; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; INFLAMMATION; KINETICS; PLASMIDS; PROMOTER REGIONS (GENETICS); RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; SERUM AMYLOID A PROTEIN; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034968842     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2001.00919.x     Document Type: Article

References (33)

1. The phenomenon of the acute phase response
2. Biosynthesis of human acute-phase serum amyloid A protein (ASAA) in vitro: The roles of mRNA accumulation, poly (A) tail shortening and translational efficiency
3. Post-transcriptional regulation of acute phase serum amyloid A2 expression by the 5′- and 3′-untranslated regions of its mRNA
4. Structure of the murine serum amyloid A gene family. Gene conversion
5. Evolution of the serum amyloid A (SAA) protein superfamily
6. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein
7. The role of NF-κB and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6
8. The kinetics and magnitude of the synergistic activation of the serum amyloid A promoter by IL-lβ and IL-6 is determined by the order of cytokine addition
9. Use of the acute phase serum amyloid A2 (SAA2) gene promoter in the analysis of pro- and anti-inflammatory mediators: Differential kinetics of SAA2 promoter induction by IL-1β and TNFα compared to IL-6
10. TNF-related ligands and their receptors
11. TNF blockade in rheumatoid arthitis: Implications for therapy and pathogenesis
12. Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor
13. Molecular cloning and expression of a receptor for human tumor necrosis factor
14. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
15. Tumor necrosis factor: Function, release and clearance
16. A human inhibitor of tumor necrosis factor α
17. Two tumor necrosis factor-binding proteins purified from human urine: Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors
18. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity
19. Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality
20. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin
21. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaniously as both TNF carriers and TNF antagonists
22. Influence of a recombinant soluble tumor necrosis factor receptor Fc Fusion protein on type II collagen-induced arthritis in mice
23. Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor α soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthitic effects
24. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75) -Fc fusion protein
25. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
26. Inflammation-induced recombinant expression in vivo using promoters from acute-phase protein genes
27. A two-component expression system that responds to inflammatory stimuli in vivo
28. Use of a promoterless Renilla luciferase vector as an internal control plasmid for transient cotransfection assays of Ras-mediated transcription activation
29. Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation
30. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1β and interleukin-6 in the human hepatoma cell line PLC/PRF/5
31. A pitfall of using a second plasmid to determine transfection efficiency
32. Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses
33. Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defence